Vapendavir is under clinical development by Altesa Biosciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vapendavir’s likelihood of approval (LoA) and phase transition for Rhinovirus Infections took place on 01 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vapendavir Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vapendavir overview

Vapendavir (BTA-798) is under development for the treatment of rhinovirus infections. Vapendavir is administered through oral route. It acts by targeting the capsid protein. It was under development for the treatment of rhinovirus infections in moderate to severe asthmatics.

Altesa Biosciences overview

Altesa Biosciences is a company that develop drugs dengue fever, yellow fever, zika, and Powassan diseases. Altesa Biosciences is headquartered in College Park, Georgia, the US.

Quick View Vapendavir LOA Data

Report Segments
  • Innovator
Drug Name
  • Vapendavir
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.